Search Results - "Lathouwers, E"

Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV‐1‐infected treatment‐naïve patients in the ARTEMIS trial by Orkin, C, DeJesus, E, Khanlou, H, Stoehr, A, Supparatpinyo, K, Lathouwers, E, Lefebvre, E, Opsomer, M, Van de Casteele, T, Tomaka, F

“…Objective This paper presents the final analysis of once‐daily darunavir/ritonavir (DRV/r) vs. lopinavir/ritonavir (LPV/r) in treatment‐naïve HIV‐1‐infected…”
Get full text

Longitudinal changes in global structural brain connectivity and cognitive performance in former hospitalized COVID-19 survivors: an exploratory study by Tassignon, B., Radwan, A., Blommaert, J., Stas, L., Allard, S. D., De Ridder, F., De Waele, E., Bulnes, L. C., Hoornaert, N., Lacor, P., Lathouwers, E., Mertens, R., Naeyaert, M., Raeymaekers, H., Seyler, L., Van Binst, A. M., Van Imschoot, L., Van Liedekerke, L., Van Schependom, J., Van Schuerbeek, P., Vandekerckhove, M., Meeusen, R., Sunaert, S., Nagels, G., De Mey, J., De Pauw, K.

“…Background Long-term sequelae of COVID-19 can result in reduced functionality of the central nervous system and substandard quality of life. Gaining insight…”
Get full text

Subgroup analysis of virological response rates with once‐ and twice‐daily darunavir/ritonavir in treatment‐experienced patients without darunavir resistance‐associated mutations in the ODIN trial by Sension, M, Cahn, P, Domingo, P, Hodder, S, Opsomer, M, Lathouwers, E, Van de Casteele, T, Tomaka, F

“…Background ODIN (once‐daily darunavir in treatment‐experienced patients) was a 48‐week, phase III, randomized, open‐label trial comparing once‐daily (qd)…”
Get full text

Non-Inferiority of Once-Daily Cobicistat-Boosted Darunavir Versus Ritonavir-Boosted Darunavir in Hiv-1-infected Adult Patients: An Adjusted Comparative Analysis of Pooled Phase 3 Data by Van Sanden, S, Thilakarathne, P, Opsomer, M, Mrus, J, Vanveggel, S, Lathouwers, E, Adriaenssen, I

Get full text

A high efficiency technique for the generation of transgenic sugar beets from stomatal guard cells by Hall, Robert D, Riksen-Bruinsma, Tjitske, Weyens, Guy J, Rosquin, Inge J, Denys, Pascale N, Evans, Ian J, Lathouwers, Jean E, Lefèbvre, Marc P, Dun well, Jim M, Tunen, Arjen van, Krens, Frans A

“…An optimized protocol has been developed for the efficient and rapid genetic modification of sugar beet (Beta vulgaris L.). A polyethylene glycol-mediated DNA…”
Get full text

PIN1 - Non-Inferiority of Once-Daily Cobicistat-Boosted Darunavir Versus Ritonavir-Boosted Darunavir in Hiv-1-infected Adult Patients: An Adjusted Comparative Analysis of Pooled Phase 3 Data by Van Sanden, S., Thilakarathne, P., Opsomer, M., Mrus, J., Vanveggel, S., Lathouwers, E., Adriaenssen, I.

Get full text

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients by DE MEYER, Sandra, LATHOUWERS, Erkki, DIERYNCK, Inge, DE PAEPE, Els, VAN BAELEN, Ben, VANGENEUGDEN, Tony, SPINOSA-GUZMAN, Sabrina, LEFEBVRE, Eric, PICCHIO, Gaston, DE BETHUNE, Marie-Pierre

“…Characterization of resistance development in virologic failure patients on the protease inhibitor darunavir administered with low-dose ritonavir (DRV/r) in…”
Get full text

Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis by Lathouwers, Erkki, De Meyer, Sandra, Dierynck, Inge, Van de Casteele, Tom, Lavreys, Ludo, de Béthune, Marie-Pierre, Picchio, Gaston

“…In the Phase III ARTEMIS Trial, treatment-naive patients received once-daily darunavir/ritonavir (DRV/r) 800/100 mg (n = 343) or lopinavir/ritonavir (LPV/r)…”
Get more information

Surface and interface effects in WSi2 formation by Duchateau, J. P. W. B., Kuiper, A. E. T., Lathouwers, E. G. C., Reader, A. H.

“…We studied the influence of a thin Fe interface layer between W and the substrate Si and of a surface W–oxide on the formation kinetics of WSi2. Auger depth…”
Get full text

Optimum implantation conditions for ion beam synthesis of buried cobalt silicide layers in Si(100) by DEKEMPENEER, E. H. A, OTTENHEIM, J. J. M, VANDENHOUDT, D. W. E, BULLE-LIEUWMA, C. W. T, LATHOUWERS, E. G. C

“…Ion beam synthesis of buried CoSi2 layers in Si(100) (Co+ energy=170 keV, dose=1.7×1017 ions cm−2) is studied as a function of implantation temperature…”
Get full text

Arsenic doping in Si-MBE using low energy ion implantation (LEII) by Collart, E.J.H., Gravesteijn, D.J., Lathouwers, E.G.C., Kersten, W.J.

“…Arsenic doping using a new, high current (> 100 μA), low energy (down to 250 eV) implanter is presented. Using this set-up it is possible to homogeneously dope…”
Get full text

Changing prevalence of darunavir resistance‐associated mutations (DRV RAMs) in clinical samples received for routine resistance testing: 2003‐2009 by De La Rosa, G, Pattery, T, Picchio, G, Lathouwers, E, Villacian, J, Van der Borght, K

“…7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK…”
Get full text

In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients by Dierynck, Inge, De Meyer, Sandra, Lathouwers, Erkki, Vanden Abeele, Carline, Van De Casteele, Tom, Spinosa-Guzman, Sabrina, de Béthune, Marie-Pierre, Picchio, Gaston

“…The effect of HIV type-1 (HIV-1) subtype on in vitro susceptibility and virological response to darunavir (DRV) and lopinavir (LPV) was studied using a broad…”
Get more information

ARTEMIS: 192‐week efficacy and safety of once‐daily darunavir/ritonavir in treatment‐naïve HIV‐1‐infected adults by Orkin, C, Dejesus, E, Khanlou, H, Stoehr, A, Supparatpinyo, K, Van De Casteele, T, Lathouwers, E, Spinosa?Guzman, S

Get full text

ARTEMIS: 192‐week efficacy and safety of once‐daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment‐naïve HIV‐1‐infected adults by Orkin, C, DeJesus, E, Khanlou, H, Stoehr, A, Supparatpinyo, K, Van de Casteele, T, Lathouwers, E, Spinosa‐Guzman, S

“…7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK…”
Get full text

O424 Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III TITAN trial in treatment-experienced patients by De Meyer, S, Lathouwers, E, Dierynck, I, De Paepe, E, Van Baelen, B, Vangeneugden, T, Tomaka, F, de Béthune, MP, Picchio, G

Get full text